Desislava Apostolova

Desislava Apostolova

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Dzhemal MotenDzhemal Moten
Dzhemal Moten
Ivanka TenevaIvanka Teneva
Ivanka Teneva
DADesislava Apostolova
Desislava Apostolova
Tsvetelina Georgieva BatsalovaTsvetelina Georgieva Batsalova
Tsvetelina Georgieva Batsalova
Balik DzhambazovBalik Dzhambazov
Balik Dzhambazov
The etiology of most autoimmune diseases, including rheumatoid arthritis (RA), remains unclear. Both genetic and environmental factors are believed to be involved in pathogenesis. Molecular mimicry is considered one of the mechanisms for the occurrence of autoimmune diseases. The aim of the study was to determine whether the bacterial peptide L-ASNase67-81, which mimics the immunodominant T-cell epitope CII259-273, can induce T-cell reactivity in blood samples from RA patients and healthy subjects through molecular mimicry. Using bioinformatic molecular modeling methods, we first determined whether the L-ASNase67-81 peptide binds to the HLA-DRB1*04:01 molecule and whether the formed MHCII–peptide complex interacts with the corresponding T-cell receptor. To validate the obtained results, leukocytes isolated from early RA patients and healthy individuals were stimulated in vitro with L-ASNase67-81 and CII259-273 peptides as well as with bacterial L-asparaginase or human type II collagen (huCII). The activated T cells (CD4+CD154+) were analyzed by flow cytometry (FACS), and the levels of cytokines produced (IL-2, IL-17A/F, and IFN-γ) were measured by ELISA. Our in silico analyses showed that the bacterial peptide L-ASNase67-81 binds better to HLA-DRB1*04:01 compared to the immunodominant T-cell epitope CII259-273, mimicking its structure and localization in the binding groove of MHCII. Six contact points were involved in the molecular interaction of the peptide with the TCR. FACS data showed that after in vitro stimulation with the L-ASNase67-81 peptide, the percentage of activated T cells (CD154+CD4+) was significantly increased in both cell cultures isolated from ERA patients and those isolated from healthy individuals, as higher values were observed for the ERA group (9.92 ± 0.23 vs. 4.82 ± 0.22). Furthermore, the ELISA assays revealed that after stimulation with L-ASNase67-81, a significant increase in the production of the cytokines IL-2, IL-17A/F, and IFN-γ was detected in the group of ERA patients. Our data showed that the bacterial L-ASNase67-81 peptide can mimic the immunodominant T-cell epitope CII259-273 and activate HLA-DRB1*04:01-restricted T cells as well as induce cytokine production in cells isolated from ERA patients. These results are the first to demonstrate that a specific bacterial antigen could play a role in the pathogenesis of RA, mimicking the immunodominant T-cell epitope from type II collagen.

Verified
Journal Article
Open access
PDF file
Sevdalina LambovaSevdalina Lambova
Sevdalina Lambova
NINina Ivanovska
Nina Ivanovska
SSStela G. Stoyanova
Stela G. Stoyanova
LBLyudmila Filipova Belenska-Todorova
Lyudmila Filipova Belenska-Todorova
EGElenka Georgieva
Elenka Georgieva
Balik DzhambazovBalik Dzhambazov
Balik Dzhambazov
Subchondral bone that has intense communication with the articular cartilage might be a potential target for pharmacological treatment in the early stages of osteoarthritis (OA). Considering the emerging data about the role of adipokines in the pathogenesis of OA, the administration of drugs that influence their level is also intriguing. Metformin and alendronate were administered in mice with collagenase-induced OA (CIOA) as a monotherapy and in combination. Safranin O staining was used for the assessment of changes in subchondral bone and articular cartilage. Before and after treatment, serum levels of visfatin and biomarkers of cartilage turnover (CTX-II, MMP-13, and COMP) were assessed. In the current study, the combined administration of alendronate and metformin in mice with CIOA led to the protection against cartilage and subchondral bone damage. In mice with CIOA, metformin led to a decrease in visfatin level. In addition, treatment with metformin, alendronate, or their combination lowered the level of cartilage biomarkers (CTX-II and COMP), while the level of MMP-13 was not influenced. In conclusion, personalized combination treatment in OA according to clinical phenotype, especially in the early stages of the disease, might lead to the identification of a successful disease-modifying therapeutic protocol in OA.

Verified
Journal Article
Open access
PDF file
Dzhemal MotenDzhemal Moten
Dzhemal Moten
Tsvetelina Georgieva BatsalovaTsvetelina Georgieva Batsalova
Tsvetelina Georgieva Batsalova
DADesislava Apostolova
Desislava Apostolova
TMTsvetelina Rumenova Mladenova
Tsvetelina Rumenova Mladenova
Balik DzhambazovBalik Dzhambazov
Balik Dzhambazov
Ivanka TenevaIvanka Teneva
Ivanka Teneva
Allergic diseases are a global public health problem that affects up to 30% of the population in industrialized societies. More than 40% of allergic patients suffer from grass pollen allergy. Grass pollen allergens of group 1 and group 5 are the major allergens, since they induce allergic reactions in patients at high rates. In this study, we used immunoinformatic approaches to design an effective epitope-based vaccine against the grass group 1 allergens. After the alignment of all known pollen T-cell and B-cell epitopes from pollen allergens available in the public databases, the epitope GTKSEVEDVIPEGWKADTSY was identified as the most suitable for further analyses. The target sequence was subjected to immunoinformatics analyses to predict antigenic T-cell and B-cell epitopes. Population coverage analysis was performed for CD8+ and CD4+ T-cell epitopes. The selected T-cell epitopes (VEDVIPEGW and TKSEVEDVIPEGWKA) covered 78.87% and 98.20% of the global population and 84.57% and 99.86% of the population of Europe. Selected CD8+, CD4+ T-cell and B-cell epitopes have been validated by molecular docking analysis. CD8+ and CD4+ T-cell epitopes showed a very strong binding affinity to major histocompatibility complex (MHC) class I (MHC I) molecules and MHC class II (MHC II) molecules with global energy scores of −72.1 kcal/mol and −89.59 kcal/mol, respectively. The human IgE-Fc (PDB ID 4J4P) showed a lower affinity with B-cell epitope (ΔG = −34.4 kcal/mol), while the Phl p 2-specific human IgE Fab (PDB ID 2VXQ) had the lowest binding with the B-cell epitope (ΔG = −29.9 kcal/mol). Our immunoinformatics results demonstrated that the peptide GTKSEVEDVIPEGWKADTSY could stimulate the immune system and we performed ex vivo tests showed that the investigated epitope activates T cells isolated from patients with grass pollen allergy, but it is not recognized by IgE antibodies specific for grass pollen allergens. This confirms the importance of such studies to establish universal epitopes to serve as a basis for developing an effective vaccine against a particular group of allergens. Further in vivo studies are needed to validate the effectiveness of such a vaccine against grass pollen allergens.

18 October 2026 in Biology
Verified
Journal Article
Open access
PDF file
GKGeorgi Kalev
Georgi Kalev
SSStela G. Stoyanova
Stela G. Stoyanova
BMBorislavlav Mateev
Borislavlav Mateev
DADesislava Apostolova
Desislava Apostolova
Dzhemal MotenDzhemal Moten
Dzhemal Moten
Tsvetelina Georgieva BatsalovaTsvetelina Georgieva Batsalova
Tsvetelina Georgieva Batsalova
Citrullination of various proteins including the major structural protein of articular cartilage, collagen type II (COL2), has been indicated to play a role in rheumatoid arthritis (RA). Humoral responses against citrullinated COL2 epitopes have also been examined in patients with another common arthritic disorder, osteoarthritis (OA), but have not been shown to be present in a substantial proportion of patients in the studied groups. To further investigate this issue, we assessed anti-COL2 epitope responses in patients with OA and RA, with particular focus on immune responses to the citrullinated form of one of the main COL2 epitopes associated with RA. This research was combined with experiments aiming to define the involvement of COL2 citrullination in these two prevalent arthritic disorders by evaluation of the presence of citrulline in normal hyaline cartilage and in purified joint COL2 from RA and OA patients. Enzyme-linked immunosorbent assays (ELISA) were performed to determine the levels of antibodies specific to COL2 epitopes (C1, U1, J1 and citrullinated C1 epitope) in blood plasma of RA patients, OA patients and control individuals that do not suffer from arthritis disorder. The relative level of citrullination of COL2 purified from normal (healthy), OA and RA hyaline cartilage was assessed by direct ELISA. Immunofluorescent staining with anti-citrulline antibody was performed on histological sections of normal cartilage. Our results demonstrate significant reactivity to COL2 and three main COL2 epitopes, including citrullinated form of COL2 (358–369) epitope, in patients with OA. Collectively, more than 90% of the patients in the OA cohort showed reactivity against COL2 (358–369) epitope and/or citrullinated COL2 (358–369), which has not been observed in previous studies. A novel finding regarding COL2 citrullination of the present study is the determined tendency for higher relative level of citrullination of COL2 from arthritic patients compared to COL2 samples from individuals that do not suffer arthritic disorder. A tendency for increased relative anti-citrulline immunoreactivity for blood plasma proteins of RA patients compared to control individuals and OA patients was detected. Positive anti-citrulline staining was observed in the perichondrium and in the extracellular matrix surrounding chondrocytes in normal cartilage. Overall, our results indicate that citrullination is a physiological process that may become altered or enhanced during joint disease leading to bone destruction.

12 November 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
MBMaria Bachvarova
Maria Bachvarova
Yordan StremskiYordan Stremski
Yordan Stremski
Stela Statkova-AbegheStela Statkova-Abeghe
Stela Statkova-Abeghe
Tsvetelina Georgieva BatsalovaTsvetelina Georgieva Batsalova
Tsvetelina Georgieva Batsalova
Dzhemal MotenDzhemal Moten
Dzhemal Moten
Balik DzhambazovBalik Dzhambazov
Balik Dzhambazov
Cancer treatment remains a major challenge in medicine due to high toxicity and drug resistance, motivating the application of novel selective cytotoxic agents based on natural compounds. In this study, ten novel benzocamalexin analogues 5a–e with variously substituted indoles were designed, synthesized, and evaluated for anticancer activity. An efficient two-step strategy was applied, involving regioselective α-amidoalkylation at C3 of indoles, followed by oxidative rearomatization of 2-(3-indolyl)-N-acylbenzothiazolines 4a–f. The use of the mild oxidant o-Chloranil in the second step enables the formation of target benzocamalexins (73–93% yield). In silico toxicological screening classified all compounds as non-mutagenic, with analogues 5b–e showing high predicted acute oral safety (LD50 = 2447.55–2486.05 mg/kg). In vitro MTT assays across human lung (A549), cervical (HeLa), and colorectal (LS180) adenocarcinoma cells, alongside normal fibroblasts (HFFC), demonstrated selective cytotoxicity. Thus, analogues 5b, 5c, and 5e displayed superior cytotoxic potency against cancer cells compared to benzocamalexin, while 4d, 5a, 5c, and 5d showed lower toxicity toward normal fibroblasts. Molecular docking with the aryl hydrocarbon receptor (AhR) predicted strong binding affinities for 5b–e (−10.1 to −10.3 kcal/mol). The AhR interaction for camalexin (−9.4 kcal/mol) and benzocamalexin (−10.0 kcal/mol) was recognized as a potential mechanism for their selective antitumour efficacy.